Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 11/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069805 | 0.90 | ALDH1A1 (0.47) | ALDH1A1TSHRGRM2LIPEBCHE | |
| SCHEMBL21159096 | 0.82 | HCRTR1 (0.43) | RETHCRTR1HCRTR2 | |
| SCHEMBL22030855 | 0.81 | TSHR (0.62) | ALDH1A1TSHRGRM2BCHEACHE | |
| SCHEMBL20160453 | 0.80 | ALDH1A1 (0.44) | ALDH1A1TSHRGRM2BCHEACHE | |
| SCHEMBL20154554 | 0.76 | RET (0.40) | RET | |
| SCHEMBL21158871 | 0.73 | CYP11B1 (0.38) | RET | |
| SCHEMBL20069809 | 0.73 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL23555159 | 0.73 | SIGMAR1 (0.48) | ALDH1A1RETHCRTR1HCRTR2 | |
| SCHEMBL20148609 | 0.73 | HCRTR1 (0.40) | ALDH1A1RETHCRTR1HCRTR2 | |
| SCHEMBL29712698 | 0.73 | ALDH1A1 (0.50) | ALDH1A1TSHRGRM2BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | ALDH1A1 2868/4885TSHR 1461/4885GRM2 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.